Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose

Karen Brown, Elaine M. Tompkins, David J. Boocock, Elizabeth A. Martin, Peter B. Farmer, Ken W Turteltaub, Esther Ubick, David Hemingway, Emma Horner-Glister, Ian N H White

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Tamoxifen is widely prescribed for the treatment of breast cancer and is also licensed in the United States for the prevention of this disease. However, tamoxifen therapy is associated with an increased occurrence of endometrial cancer in women, and there is also evidence that it may elevate the risk of colorectal cancer. The underlying mechanisms responsible for tamoxifen-induced carcinogenesis in women have not yet been elucidated, but much interest has focused on the role of DNA adduct formation. We investigated the propensity of tamoxifen to bind irreversibly to colorectal DNA when given to 10 women as a single [14C]-labeled therapeutic (20 mg) dose, ∼18 h before undergoing colon resections. Using the sensitive technique of accelerator mass spectrometry, coupled with high-performance liquid chromatography separation of enzymatically digested DNA, a peak corresponding to authentic dG-N 2-tamoxifen adduct was detected in samples from three patients, at levels ranging from 1 to 7 adducts/109 nucleotides. No [ 14C]-radiolabel associated with tamoxifen or its major metabolites was detected. The presence of detectable CYP3A4 protein in all colon samples suggests that this tissue has the potential to activate tamoxifen to α-hydroxytamoxifen, in addition to that occurring in the systemic circulation, and direct interaction of this metabolite with DNA could account for the binding observed. Although the level of tamoxifen-induced damage displayed a degree of interindividual variability, when present, it was ∼10 to 100 times higher than that reported for other suspect human colon carcinogens such as 2-amino-1-methyl-6-phenyimidazo[4,5-b]pyridine. These findings provide a mechanistic basis through which tamoxifen could increase the incidence of colon cancers in women.

Original languageEnglish (US)
Pages (from-to)6995-7002
Number of pages8
JournalCancer Research
Volume67
Issue number14
DOIs
StatePublished - Jul 15 2007
Externally publishedYes

Fingerprint

DNA Adducts
Tamoxifen
Colon
Therapeutics
DNA
Cytochrome P-450 CYP3A
Endometrial Neoplasms
Carcinogens
Colonic Neoplasms
Colorectal Neoplasms
Mass Spectrometry
Carcinogenesis
Nucleotides
High Pressure Liquid Chromatography
Breast Neoplasms
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brown, K., Tompkins, E. M., Boocock, D. J., Martin, E. A., Farmer, P. B., Turteltaub, K. W., ... White, I. N. H. (2007). Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose. Cancer Research, 67(14), 6995-7002. https://doi.org/10.1158/0008-5472.CAN-07-0913

Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose. / Brown, Karen; Tompkins, Elaine M.; Boocock, David J.; Martin, Elizabeth A.; Farmer, Peter B.; Turteltaub, Ken W; Ubick, Esther; Hemingway, David; Horner-Glister, Emma; White, Ian N H.

In: Cancer Research, Vol. 67, No. 14, 15.07.2007, p. 6995-7002.

Research output: Contribution to journalArticle

Brown, K, Tompkins, EM, Boocock, DJ, Martin, EA, Farmer, PB, Turteltaub, KW, Ubick, E, Hemingway, D, Horner-Glister, E & White, INH 2007, 'Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose', Cancer Research, vol. 67, no. 14, pp. 6995-7002. https://doi.org/10.1158/0008-5472.CAN-07-0913
Brown, Karen ; Tompkins, Elaine M. ; Boocock, David J. ; Martin, Elizabeth A. ; Farmer, Peter B. ; Turteltaub, Ken W ; Ubick, Esther ; Hemingway, David ; Horner-Glister, Emma ; White, Ian N H. / Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose. In: Cancer Research. 2007 ; Vol. 67, No. 14. pp. 6995-7002.
@article{22ebec5cf8314be98a4c7c014c5fb59e,
title = "Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose",
abstract = "Tamoxifen is widely prescribed for the treatment of breast cancer and is also licensed in the United States for the prevention of this disease. However, tamoxifen therapy is associated with an increased occurrence of endometrial cancer in women, and there is also evidence that it may elevate the risk of colorectal cancer. The underlying mechanisms responsible for tamoxifen-induced carcinogenesis in women have not yet been elucidated, but much interest has focused on the role of DNA adduct formation. We investigated the propensity of tamoxifen to bind irreversibly to colorectal DNA when given to 10 women as a single [14C]-labeled therapeutic (20 mg) dose, ∼18 h before undergoing colon resections. Using the sensitive technique of accelerator mass spectrometry, coupled with high-performance liquid chromatography separation of enzymatically digested DNA, a peak corresponding to authentic dG-N 2-tamoxifen adduct was detected in samples from three patients, at levels ranging from 1 to 7 adducts/109 nucleotides. No [ 14C]-radiolabel associated with tamoxifen or its major metabolites was detected. The presence of detectable CYP3A4 protein in all colon samples suggests that this tissue has the potential to activate tamoxifen to α-hydroxytamoxifen, in addition to that occurring in the systemic circulation, and direct interaction of this metabolite with DNA could account for the binding observed. Although the level of tamoxifen-induced damage displayed a degree of interindividual variability, when present, it was ∼10 to 100 times higher than that reported for other suspect human colon carcinogens such as 2-amino-1-methyl-6-phenyimidazo[4,5-b]pyridine. These findings provide a mechanistic basis through which tamoxifen could increase the incidence of colon cancers in women.",
author = "Karen Brown and Tompkins, {Elaine M.} and Boocock, {David J.} and Martin, {Elizabeth A.} and Farmer, {Peter B.} and Turteltaub, {Ken W} and Esther Ubick and David Hemingway and Emma Horner-Glister and White, {Ian N H}",
year = "2007",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-07-0913",
language = "English (US)",
volume = "67",
pages = "6995--7002",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose

AU - Brown, Karen

AU - Tompkins, Elaine M.

AU - Boocock, David J.

AU - Martin, Elizabeth A.

AU - Farmer, Peter B.

AU - Turteltaub, Ken W

AU - Ubick, Esther

AU - Hemingway, David

AU - Horner-Glister, Emma

AU - White, Ian N H

PY - 2007/7/15

Y1 - 2007/7/15

N2 - Tamoxifen is widely prescribed for the treatment of breast cancer and is also licensed in the United States for the prevention of this disease. However, tamoxifen therapy is associated with an increased occurrence of endometrial cancer in women, and there is also evidence that it may elevate the risk of colorectal cancer. The underlying mechanisms responsible for tamoxifen-induced carcinogenesis in women have not yet been elucidated, but much interest has focused on the role of DNA adduct formation. We investigated the propensity of tamoxifen to bind irreversibly to colorectal DNA when given to 10 women as a single [14C]-labeled therapeutic (20 mg) dose, ∼18 h before undergoing colon resections. Using the sensitive technique of accelerator mass spectrometry, coupled with high-performance liquid chromatography separation of enzymatically digested DNA, a peak corresponding to authentic dG-N 2-tamoxifen adduct was detected in samples from three patients, at levels ranging from 1 to 7 adducts/109 nucleotides. No [ 14C]-radiolabel associated with tamoxifen or its major metabolites was detected. The presence of detectable CYP3A4 protein in all colon samples suggests that this tissue has the potential to activate tamoxifen to α-hydroxytamoxifen, in addition to that occurring in the systemic circulation, and direct interaction of this metabolite with DNA could account for the binding observed. Although the level of tamoxifen-induced damage displayed a degree of interindividual variability, when present, it was ∼10 to 100 times higher than that reported for other suspect human colon carcinogens such as 2-amino-1-methyl-6-phenyimidazo[4,5-b]pyridine. These findings provide a mechanistic basis through which tamoxifen could increase the incidence of colon cancers in women.

AB - Tamoxifen is widely prescribed for the treatment of breast cancer and is also licensed in the United States for the prevention of this disease. However, tamoxifen therapy is associated with an increased occurrence of endometrial cancer in women, and there is also evidence that it may elevate the risk of colorectal cancer. The underlying mechanisms responsible for tamoxifen-induced carcinogenesis in women have not yet been elucidated, but much interest has focused on the role of DNA adduct formation. We investigated the propensity of tamoxifen to bind irreversibly to colorectal DNA when given to 10 women as a single [14C]-labeled therapeutic (20 mg) dose, ∼18 h before undergoing colon resections. Using the sensitive technique of accelerator mass spectrometry, coupled with high-performance liquid chromatography separation of enzymatically digested DNA, a peak corresponding to authentic dG-N 2-tamoxifen adduct was detected in samples from three patients, at levels ranging from 1 to 7 adducts/109 nucleotides. No [ 14C]-radiolabel associated with tamoxifen or its major metabolites was detected. The presence of detectable CYP3A4 protein in all colon samples suggests that this tissue has the potential to activate tamoxifen to α-hydroxytamoxifen, in addition to that occurring in the systemic circulation, and direct interaction of this metabolite with DNA could account for the binding observed. Although the level of tamoxifen-induced damage displayed a degree of interindividual variability, when present, it was ∼10 to 100 times higher than that reported for other suspect human colon carcinogens such as 2-amino-1-methyl-6-phenyimidazo[4,5-b]pyridine. These findings provide a mechanistic basis through which tamoxifen could increase the incidence of colon cancers in women.

UR - http://www.scopus.com/inward/record.url?scp=34547105315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547105315&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0913

DO - 10.1158/0008-5472.CAN-07-0913

M3 - Article

C2 - 17638912

AN - SCOPUS:34547105315

VL - 67

SP - 6995

EP - 7002

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 14

ER -